Get the Stockscreener App
72.31
5.56%
3.81
Pre-market:
72.45
0.14
+0.19%
Apogee Therapeutics Inc stock is traded at $72.31, with a volume of 1.36M.
It is up +5.56% in the last 24 hours and up +11.45% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$68.50
Open:
$70.3
24h Volume:
1.36M
Relative Volume:
1.42
Market Cap:
$4.94B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-26.26
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
+2.00%
1M Performance:
+11.45%
6M Performance:
+94.75%
1Y Performance:
+138.10%
1-Day Range:
$69.34
$74.09
1-Week Range:
$66.00
$74.09
52-Week Range:
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
72.31 | 4.68B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Rafferty Asset Management LLC Acquires 23,585 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference - Yahoo Finance
Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)? - Yahoo Finance
Apogee Therapeutics (APGE) Stock Analysis: Exploring a 47.76% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $95.00 - MarketBeat
RBC Lowers Price Target on Apogee Therapeutics to $82 From $83, Keeps Sector Perform, Speculative Risk - marketscreener.com
Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability - TipRanks
Decoding Apogee Therapeutics Inc (APGE): A Strategic SWOT Insigh - GuruFocus
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook By Investing.com - Investing.com Australia
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook - Investing.com
Key facts: Apogee Therapeutics posts $285.6M loss; plans Phase 3 trial - TradingView
APGE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Apogee Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Apogee Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Adjusts Price Target on Apogee Therapeutics to $95 From $90, Maintains Outperform Rating - marketscreener.com
APOGEE THERAPEUTICS ($APGE) Releases Q4 2025 Earnings - Quiver Quantitative
Apogee Therapeutics (NASDAQ:APGE) Releases Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
APGE: Strong pipeline progress and robust cash reserves position for key data and trial milestones in 2026 - TradingView
Apogee Therapeutics 2025 10-K: $0 Revenue; EPS $(4.22) - TradingView
Apogee Therapeutics (NASDAQ: APGE) advances long-acting AD biologics - Stock Titan
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results - ChartMill
Precision Trading with Apogee Therapeutics Inc. (APGE) Risk Zones - Stock Traders Daily
JPMorgan Chase & Co. Purchases 417,161 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
APGE SEC FilingsApogee Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - The Motley Fool
Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Promising Biotech with Nearly 50% Upside Potential - DirectorsTalk Interviews
Apogee Therapeutics to Participate in Upcoming March Conferences - The Manila Times
Biotech roadshow: Apogee Therapeutics plans three March conferences - Stock Titan
Apogee Therapeutics (APGE) Expected to Announce Earnings on Monday - Defense World
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - Yahoo Finance
Aberdeen Group plc Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating - MSN
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
What is Apogee Therapeutics Inc. s 5 year growth outlookJuly 2025 Rallies & Stock Market Timing Techniques - mfd.ru
End of Apogee (APGE) drug collaboration leads to revised analyst expectations - MSN
Apogee Therapeutics Rings the Closing Bell - Nasdaq
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations - Finviz
Technical Reactions to APGE Trends in Macro Strategies - Stock Traders Daily
Apogee Therapeutics (APGE) Stock Analysis: A Biotech Gem With 53.86% Potential Upside - DirectorsTalk Interviews
Is Apogee Therapeutics (APGE) Now Defined by Its IL-13/OX40L Positioning Against Sanofi? - Yahoo Finance
Here is Why Apogee Therapeutics (APGE) Appears Attractive - Yahoo Finance
CEO Moves: What is Apogee Therapeutics Inc. s 5 year growth outlook2025 Market WrapUp & Weekly Top Gainers Trade List - mfd.ru
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million - Yahoo Finance
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc - GuruFocus
Apogee Therapeutics CEO Sells 20,000 Shares - TradingView
What’s the beta of Apogee Therapeutics Inc. stockTrade Volume Report & Technical Pattern Alert System - mfd.ru
Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference - MarketBeat
Page not foundAirwhon - MarketBeat
APGE: Quarterly dosing, rapid itch relief, and strong safety set up a 2029 launch to challenge market leaders - TradingView
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):